CenterBook Partners LP raised its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 304.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 249,510 shares of the company’s stock after acquiring an additional 187,752 shares during the period. CenterBook Partners LP’s holdings in Stevanato Group were worth $5,020,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming raised its stake in Stevanato Group by 39,216.7% during the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after acquiring an additional 2,353 shares in the last quarter. Quantbot Technologies LP bought a new stake in Stevanato Group during the 3rd quarter valued at $68,000. Tower Research Capital LLC TRC raised its stake in Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after acquiring an additional 4,250 shares in the last quarter. Van Berkom & Associates Inc. raised its stake in Stevanato Group by 55.4% during the 4th quarter. Van Berkom & Associates Inc. now owns 5,617 shares of the company’s stock valued at $113,000 after acquiring an additional 2,002 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Stevanato Group by 391.4% during the 4th quarter. Farther Finance Advisors LLC now owns 8,324 shares of the company’s stock valued at $167,000 after acquiring an additional 6,630 shares in the last quarter.
Stevanato Group Stock Up 0.7%
STVN opened at €18.58 on Monday. Stevanato Group S.p.A. has a one year low of €12.89 and a one year high of €28.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The stock’s fifty day moving average is €16.40 and its 200-day moving average is €17.77. The company has a market capitalization of $5.63 billion, a PE ratio of 31.49, a P/E/G ratio of 1.70 and a beta of 0.78.
Stevanato Group Cuts Dividend
The company also recently disclosed an annual dividend, which will be paid on Wednesday, July 29th. Stockholders of record on Thursday, June 11th will be paid a $0.054 dividend. This represents a dividend yield of 29.0%. The ex-dividend date of this dividend is Thursday, June 11th.
Analyst Ratings Changes
Several analysts have weighed in on the company. Morgan Stanley cut their target price on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th. Wolfe Research assumed coverage on Stevanato Group in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $21.00 target price on the stock. Citigroup cut their target price on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. KeyCorp cut their target price on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Finally, Jefferies Financial Group set a $17.50 target price on Stevanato Group in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Read Our Latest Research Report on STVN
Stevanato Group Company Profile
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.
Featured Articles
- Five stocks we like better than Stevanato Group
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN – Free Report).
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
